Skip to main content

Table 1 Characteristics of the cohort of patients

From: Radiation treatment with volumetric modulated arc therapy of hepatocellular carcinoma patients. Early clinical outcome and toxicity profile from a retrospective analysis of 138 patients

Characteristics Items N (%)
Sex Female 26 (18.4%)
  Male 112 (79.4%)
Age Mean 64
  Median (range) 66 (30–87)
  St.dev 11
Portal Vein Thrombosis No 64 (46.4%)
  Yes 74 (53.6%)
Tumor location Right lobe 57 (41.3%)
  Left lobe 10 (7.2%)
  Bilateral lobe 71 (51.4%)
Stage T T1 8 (5.8%)
  T2 10 (7.2%)
  T3 120 (86.9%)
Stage N N0 114 (82.60%)
  N1 24 (17.4%)
Stage M M0 116 (84.1%)
  M1 22 (15.9%)
AJCC Stage I 7 (5.1%)
  II 9 (6.5%)
  III 83 (60.1%)
  IV 39 (28.3%)
Okuda Stage I 31 (22.4%)
  II 107 (77.6%)
BCLC Stage A 9 (6.5%)
  B 29 (21.0%)
  C 100 (72.5%)
Child-Pugh Stage A 96 (69.6%)
  B 42 (30.4%)
Hepatitis No 19 (13.8%)
  B 71 (51.4%)
  C 43 (31.2%)
  B and C 5 (3.6%)
Initial Alpha-fetoprotein (?g/L) Median (range) 11481 (2.4 – >58300)
Initial white blood count (kU/?L) Median (range) 5.9 (2.7 – 15.6)
Initial haemoglobin level (g/dL) Median (range) 12.8 (7.0 – 19.0)
Initial GPT level (U/L) Median (range) 50.0 (8.8 – 396.0)
Initial total bilirubin level (mg/dL) Median (range) 0.9 (0.3 – 8.5)
Initial tumor volume (cm3) Median (range) 516 (28 – 3621)
Total liver volume (cm3) Median (range) 1587 (548 – 5489)
Dose prescription 45Gy 16 (11.6%)
  60Gy 114 (82.6%)
  66Gy 8 (5.8%)
  1. Values refer to number of patients, % to the total number of 138 patients.
  2. AJCC: American joint Committee on Cancer, BCLC: Barcelona Clinic Liver Cancer. HCC: hepatocellular carcinoma. TACE: transarterial chemo-embolisation. RFA: radio-frequency ablation. GPT: Glutamic Pyruvic Transaminase.